Patient Data

Exhibits

Click to mark whether the assessment finding represents a therapeutic result of the minoxidil administered, a nontherapeutic side effect, or an unrelated finding. Each row must have one option selected.

• Methemoglobinemia: Methemoglobinemia is characterized by hypoxia symptoms despite normal oxygen saturation readings. However, this condition is very rare in asthma patients and is typically associated with certain medications or chemical exposures, not beta-agonist overuse like albuterol.
• Anemia: Anemia could cause dizziness and lightheadedness, but it would not explain palpitations triggered by excessive albuterol use. The acute worsening of symptoms with a background of asthma and heavy beta-agonist use points away from anemia as the primary concern.
• Anaphylaxis: Anaphylaxis presents with airway swelling, hypotension, wheezing, and respiratory compromise. Since the client’s oxygen saturation is excellent (99%) and no wheezing or airway edema is noted, anaphylaxis is unlikely in this scenario.
• Tachydysrhythmia: Tachydysrhythmia is the most likely diagnosis because overuse of albuterol stimulates beta receptors, leading to increased heart rate, palpitations, dizziness, and lightheadedness. This aligns precisely with the client's reported symptoms and assessment findings.
• Administer diphenhydramine: Diphenhydramine is an antihistamine used primarily for allergic reactions and anaphylaxis. There is no evidence of an allergic process in this client; thus, administering diphenhydramine would not address the cardiac symptoms from probable tachydysrhythmia.
• Give a dose of albuterol: Administering more albuterol would likely worsen the tachydysrhythmia, as beta-agonists increase heart rate and myocardial oxygen demand. Since the problem stems from albuterol overuse, giving another dose would be inappropriate and harmful.
• Take a set of baseline vital signs: Taking a set of baseline vital signs is essential because it provides a foundation for assessing current cardiovascular stability. It would help establish the severity of the tachycardia and guide further intervention strategies.
• Place the client on a cardiorespiratory monitor: Placing the client on a cardiorespiratory monitor is critical to continuously assess heart rate, rhythm, and potential arrhythmias. This allows immediate detection of life-threatening patterns such as supraventricular tachycardia or ventricular ectopy.
• Draw blood for a complete blood count: Drawing a CBC would help if there was suspicion of anemia or infection, but the clinical picture points primarily toward a cardiac rhythm problem. This diagnostic step would not be immediately necessary based on the current situation.
• Methemoglobin level: Monitoring methemoglobin levels would be appropriate if the client had cyanosis or unexplained hypoxia without respiratory distress. Since the oxygen saturation is excellent, checking methemoglobin is not relevant to her current condition.
• Iron level: Monitoring iron levels is important in diagnosing chronic anemia, but anemia is not the primary issue here. The focus should remain on cardiovascular monitoring because the immediate symptoms suggest arrhythmia rather than a hematologic cause.
• Breath sounds: Although the client currently has no wheezing, regular assessment of breath sounds is necessary to detect any developing bronchospasm or respiratory deterioration, especially given her underlying asthma diagnosis and recent respiratory strain.
• Airway edema: Monitoring for airway edema would be essential if anaphylaxis were suspected. Since there are no signs of respiratory distress, stridor, or swelling, airway edema monitoring is less relevant compared to cardiac monitoring in this situation.
• Heart rate and rhythm: Heart rate and rhythm must be continuously monitored because the client is exhibiting signs of tachydysrhythmia. Detecting arrhythmias early enables prompt treatment and reduces the risk of serious cardiac complications like syncope or cardiac arrest.

A. Document the client's refusal of the medication at this time: While documentation is necessary if a medication is refused, the priority is to educate the client first. The nurse should explain the proper timing of sucralfate to promote understanding and adherence rather than simply accepting refusal.

B. Explain the need to take the medication at least 1 hour before meals: Sucralfate acts by forming a protective barrier over ulcerated mucosa and must be taken on an empty stomach for maximum effectiveness. Administering it one hour before meals ensures the stomach lining is properly coated before food intake.

C. Allow the client to take the medication up to 1 hour after breakfast: Taking sucralfate after a meal diminishes its ability to bind effectively to the mucosa. Food interferes with its action, so post-meal dosing is inappropriate for achieving therapeutic benefit.

D. Instruct the client to take it when the meal tray is delivered: Taking sucralfate at mealtime is too late for optimal therapeutic effect. At that point, gastric contents may interfere with its binding to ulcerated areas, reducing its protective action.